Prognosis
Pfizer, BioNTech to Supply Up to 40 Million Shots to Covax
- Vaccine to be offered on a not-for-profit basis, Pfizer says
- Covax alliance aims to boost immunization around the world
This article is for subscribers only.
Pfizer Inc. and BioNTech SE will supply as many as 40 million doses of their Covid-19 vaccine to Covax, a global alliance many poorer countries are relying on to protect their populations.
Shipments will start in the first quarter and continue throughout 2021, the companies said in a statement. The agreement follows pacts with AstraZeneca Plc, whose shot is approved in the U.K., and other drugmakers such as Johnson & Johnson that are working on potential vaccines.